Sai Parenterals Limited: Transcript of Q1 FY'27 Earnings Call Released

Sai Parenterals Limited has released the transcript of its Q1 FY'27 earnings conference call, which was held on August 12, 2026. The call provided insights into the company's financial performance and strategic developments.

Financially, consolidated total revenue for Q1 FY'27 stood at ₹182 crore, with a gross profit of ₹76 crore (41.8% margin) and EBITDA of ₹27 crore (14.9% margin). Profit after tax was ₹8 crore (4.3% margin). The company's full-year revenue target is ₹750 crore, with Q1 representing approximately 24% of this target, ahead of projections given the 45:55 split expected between the two halves of the fiscal year. Gross margins improved sequentially to 41.8% from 38.1% in Q4 FY'26 due to a lag in price revision realization. However, elevated air freight costs in Australia, necessitated by supply chain disruptions in West Asia, impacted margins.

Strategically, the Board of Directors approved a proposed variation in the objects of the IPO issue. The company plans to redeploy ₹83.83 crore, originally earmarked for manufacturing facility upgrades, and ₹18.02 crore for an R&D center, towards acquiring majority stakes in two operating pharmaceutical assets. The aggregate amount involved is ₹101.85 crore, subject to shareholder approval. This variation is driven by a change in regulatory position in Hyderabad, where upgradations within the outer ring road are no longer permitted, and physical constraints at the existing Jeedimetla site. The company proposes to acquire a 60% equity stake in Saicriti Pharma Private Limited for ₹83.83 crore, which is constructing a critical care injectable facility at Gummadidala. This investment will result in approximately 154.66 million units of injectable capacity, a 47% increase over the original plan. Alongside this, the company gains access to Saicriti's existing domestic critical care franchise of approximately ₹52 crore. In a second transaction, the company's R&D subsidiary proposes to acquire a 60% equity in Prathyak Laboratories Private Limited for ₹15 crore. Prathyak operates an established R&D center with a pipeline of 150 SKUs across 86 molecules. This acquisition is expected to complete by September 30, 2026.

In Australia, the company has infused AUD 1.75 million of the balance AUD 1.7 million required to complete the Australian facility, bringing the total funding for Australian programs to AUD 53 million. Physical completion of the Australian facility is targeted for January 2027, with TGA licensing inspection anticipated by March 31, 2027, and Phase 1 manufacturing expected from April 2027. The company also approved the incorporation of a subsidiary in the United States to evaluate market entry.

The company reiterated its guidance of ₹750 crore in revenue for FY'27 at an EBITDA margin of around 17%, emphasizing that FY'27 is a year of building, with FY'28 expected to show performance improvements. The earnings call also included discussions on the Australian and New Zealand platform, the renewal of an exclusive OTC supply agreement with EBOS Group valued at AUD 202 million (approximately ₹1,300 crore) for 7.5 years, and the financial performance on a standalone basis, where revenue grew by 175% year-on-year to ₹56 crore.